Heart failure (HF) is classified as acute or chronic, and both settings are the focus of this report. Although much progress has been made in the pharmacological management of HF, it mainly relates to chronic HF (CHF), particularly HF with reduced ejection fraction (HFrEF); significant unmet need remains in the treatment of HF with preserved ejection fraction (HFpEF). Additionally, the treatment of acute HF (AHF) is dominated by old, generic products. This report provides insights into the current and future CHF and AHF therapy markets, the performance of current market leader Entresto, and the expected dynamics of the HFrEF and HFpEF therapy markets following the entries of several new therapies (Boehringer Ingelheim / Eli Lilly’s Jardiance, AstraZeneca’s Farxiga, Bayer / Merck Sharp & Dohme’s vericiguat, Amgen / Cytokinetics’ omecamtiv mecarbil, and Bayer’s finerenone). This report also assesses how the AHF market will evolve given the lack of new drug launches in this patient population.
- How large are the treatable AHF, HFrEF, and HFpEF populations, and how will diagnosis rates change over time?
- What is the state of treatment in heart failure? What are the most important drugs and why? What clinical needs remain unfulfilled?
- How will the use of Entresto evolve over the forecast period?
- How will the treatment of HFpEF change following the launches of the first evidence-based drugs for this population?
- For which emerging therapies do thought leaders express the most enthusiasm, and what level of market penetration can they expect?
United States, EU5, Japan
20 country-specific interviews with thought-leading cardiologists; supported by survey data collected for this and other DRG research.
Diagnosed events of AHF by country and diagnosed prevalence of CHF by country, segmented by ejection fraction.
10-year, annualized, drug-level sales and patient shares of key HF therapies through 2029, segmented by brands / generics and ejection fraction (HFrEF and HFpEF).
Phase III/PR: 7 drugs; Phase II: 10 drugs
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
- Heart Failure - Landscape & Forecast - Disease Landscape & Forecast
Author(s): Dominika Rudnicka-Noulin, PhD, MSc; Sunali D. Goonesekera, SM
Dominika Rudnicka-Noulin, PhD, MSc is a senior business insights analyst in the Cardiovascular, Metabolic and Renal division at Decision Resources Group, specializing in cardiovascular diseases, with expertise in heart failure and acute coronary syndrome.
Prior to joining DRG, Dominika held a position of an associate editor at Nature Communications, working across a variety of therapy areas. Dominika also worked for three years as a Postdoctoral Research Associate on a joint project between Imperial College London and MedImmune aimed at developing more potent antibody-based drugs. Dominika gained her PhD at the Institut Pasteur in Paris, France where her work was funded by the European Commission Marie Skłodowska-Curie Actions
Sunali Goonesekera is an Associate Epidemiologist at Decision Resources Group.
Sunali holds a Master’s degree in Epidemiology from the Harvard School of Public Health and a B.A. in Biology (Honors) from Dartmouth College. Prior to joining Decision Resources Group, Sunali conducted epidemiological research and lead authored two manuscripts on racial/ethnic disparities in metabolic diseases at the New England Research Institutes. She has contributed to multiple publications in peer-reviewed journals in epidemiology and in the biological sciences.